Search results
Results From The WOW.Com Content Network
No participants had received a COVID‑19 vaccine or been previously infected with COVID‑19. [12] The main outcome measured in the trial was the proportion of people who were hospitalized due to COVID‑19 or died due to any cause during 28 days of follow-up. [12] EPIC-HR started in July 2021, and completed in December 2021. [46]
The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1] [2] [3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the ...
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death.
COVID-19. Pfizer. 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine. HIV. non- nucleoside reverse transcriptase inhibitor. Nitazoxanide. Broad-spectrum antiviral.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
In the European Union, the combination is indicated for the treatment of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID‑19; and for the prevention of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb).
Molnupiravir. Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [ 7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [ 7] It is taken by mouth. [ 7] Molnupiravir is a prodrug of the synthetic nucleoside derivative N4 -hydroxy cytidine and exerts its ...
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It is one of the four pillars of the ...